Abstract
The formal C-20 methylation of 1,25-dihydroxy vitamin D3 (calcitriol) and bridging of two methyl groups produces spiro[cyclopropane-1, 20-calcitriol], colloquially referred to as C-20 cyclopropylcalcitriol, which is much more active in MLR for suppression of interferon-γ release than calcitriol, and hypercalcemia in mice is elicited at a ten-fold lower dose when compared to calcitriol. Introduction of the Δ16,17-double bond, modification of the side chain by 23- unsaturation and replacement of the methyl groups at C-26 and C-27 with trifluoromethyl moieties create a highly active series of vitamin D analogs. As previously observed in the calcitriol series, the presence of the C-16 double bond in the cyclopropyl analogs also arrests metabolic side-chain oxidation in the at the C-24 oxo level in UMR 106 cells. The enhanced biological activity is ascribed, at least in part, to the improved resistance toward metabolic degradation.
Keywords: hydrogenation, Transactivation, Prostate tumor, UMR 106 cells, 20-cyclopropyl analogs
Current Topics in Medicinal Chemistry
Title: C-20 Cyclopropyl Vitamin D3 Analogs
Volume: 6 Issue: 12
Author(s): Milan R. Uskokovic, Percy Manchand, Stanislaw Marczak, Hubert Maehr, Pawel Jankowski, Luciano Adorini and G. Satyanarayana Reddy
Affiliation:
Keywords: hydrogenation, Transactivation, Prostate tumor, UMR 106 cells, 20-cyclopropyl analogs
Abstract: The formal C-20 methylation of 1,25-dihydroxy vitamin D3 (calcitriol) and bridging of two methyl groups produces spiro[cyclopropane-1, 20-calcitriol], colloquially referred to as C-20 cyclopropylcalcitriol, which is much more active in MLR for suppression of interferon-γ release than calcitriol, and hypercalcemia in mice is elicited at a ten-fold lower dose when compared to calcitriol. Introduction of the Δ16,17-double bond, modification of the side chain by 23- unsaturation and replacement of the methyl groups at C-26 and C-27 with trifluoromethyl moieties create a highly active series of vitamin D analogs. As previously observed in the calcitriol series, the presence of the C-16 double bond in the cyclopropyl analogs also arrests metabolic side-chain oxidation in the at the C-24 oxo level in UMR 106 cells. The enhanced biological activity is ascribed, at least in part, to the improved resistance toward metabolic degradation.
Export Options
About this article
Cite this article as:
Uskokovic R. Milan, Manchand Percy, Marczak Stanislaw, Maehr Hubert, Jankowski Pawel, Adorini Luciano and Reddy G. Satyanarayana, C-20 Cyclopropyl Vitamin D3 Analogs, Current Topics in Medicinal Chemistry 2006; 6 (12) . https://dx.doi.org/10.2174/156802606777864962
DOI https://dx.doi.org/10.2174/156802606777864962 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Cell-Type Specificity and Endosomal Escape of Cell-Penetrating Peptides
Current Pharmaceutical Design The Role of Imaging in Computer-Assisted Tumor Surgery of the Sacrum and Pelvis
Current Medical Imaging Aryltetralin-type Lignan of Podophyllum: A Comprehensive Review
The Natural Products Journal The Role of YY1 in Oncogenesis and Its Potential as a Drug Target in Cancer Therapies
Current Cancer Drug Targets Peptide Nucleic Acids with a Structurally Biased Backbone: Effects of Conformational Constraints and Stereochemistry
Current Topics in Medicinal Chemistry Alternative Splicing in Chronic Myeloid Leukemia (CML): A Novel Therapeutic Target?
Current Cancer Drug Targets Molecular Mechanisms Underlying Psychological Stress and Cancer
Current Pharmaceutical Design Clinical Pharmacology of Cyclophosphamide and Ifosfamide
Current Drug Therapy Biomarkers and Osteosarcoma and IGF
Recent Patents on Biomarkers The Synergistic Effects of DNA-Targeted Chemotherapeutics and Histone Deacetylase Inhibitors As Therapeutic Strategies for Cancer Treatment
Current Medicinal Chemistry Mechanisms of Drug Resistance in Cancer Chemotherapy: Coordinated Role and Regulation of Efflux Transporters and Metabolizing Enzymes
Current Pharmaceutical Design Celecoxib and Dimethylcelecoxib Block Oxidative Phosphorylation, Epithelial-Mesenchymal Transition and Invasiveness in Breast Cancer Stem Cells
Current Medicinal Chemistry An Overview on the Role of miR-451 in Lung Cancer: Diagnosis, Therapy, and Prognosis
MicroRNA Assessment of Bishosphonate Activity In Vitro
Current Pharmaceutical Design Radiosensitization of Prostate Cancer by Soy Isoflavones
Current Cancer Drug Targets Therapeutic Agents Based on DNA Sequence Specific Binding
Current Topics in Medicinal Chemistry Ewing Sarcoma Family Tumors: Past, Present and Future Prospects
Current Cancer Therapy Reviews Classification of Sarcomas Using Bioinformatics and Molecular Profiling
Current Pharmaceutical Biotechnology Inhibition of Lysozyme by Taurine Dibromamine
Protein & Peptide Letters Anlotinib Overcomes Multiple Drug Resistant Colorectal Cancer Cells via Inactivating PI3K/AKT Pathway
Anti-Cancer Agents in Medicinal Chemistry